Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis
Sponsor: Xencor, Inc.
Summary
The purpose of this study is to determine the safety and tolerability of XmAb13676 in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
Official title: A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
47
Start Date
2025-10-21
Completion Date
2028-06
Last Updated
2025-11-17
Healthy Volunteers
No
Conditions
Interventions
XmAb13676
Biological
Locations (4)
Arensia Research Clinic
Tbilisi, Georgia
Xencor Investigative Site
Tbilisi, Georgia
Arensia Research Clinic
Chisinau, Moldova
Xencor Investigative Site
Auckland, New Zealand